| Literature DB >> 2813811 |
H Nagai1, T Shimazawa, I Yakuo, M Aoki, A Koda, M Kasahara.
Abstract
The role of thromboxane A2 (TxA2) in CCl4-induced liver disease was investigated in mice. Significant elevation of TxB2 in the liver was observed 6 hours after the injection of CCl4. Administration of OKY-046, a selective TxA2 synthetase inhibitor (10 and 50 mg/kg) and ONO-3708, a TxA2 receptor antagonist, (0.5, 1 and 2 mg/Kg) suppressed the elevation of serum GOT and GPT levels and histopathological changes of the liver. In addition, OKY-046 inhibited the elevation of TxB2 in the liver. When U-46619, a stable TxA2 mimetic was injected i.v. into the mice, clear elevation of serum GOT and GPT levels and histopathological score of the liver were observed. These results suggest that TxA2 play a role for the onset of CCl4-induced liver injury in mice.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2813811 DOI： 10.1016/0090-6980(89)90126-3
Source DB: PubMed Journal: Prostaglandins ISSN： 0090-6980